Overview
Senti Biosciences Q3 net loss was $18.1 mln, with EPS of -$0.69
Cash and cash equivalents decreased to $12.2 mln from $48.3 mln at end of 2024
R&D expenses rose to $10.5 mln, driven by higher external services and personnel costs
Result Drivers
R&D EXPENSES - R&D expenses increased due to higher external services and personnel costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.69 | ||
Q3 Net Income | -$18.1 mln | ||
Q3 Operating Expenses | $16.95 mln | ||
Q3 Operating Income | -$16.95 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Senti Biosciences Inc is $12.00, about 84.2% above its November 12 closing price of $1.89
Press Release: ID:nGNX7Y1DH5
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)